Juli 2022: Menurut penelitian terbaru yang dilakukan oleh Emergen Research, pasar global untuk terapi sel T CAR mencapai ukuran USD 1.29 miliar pada tahun 2021 dan diperkirakan akan mencatatkan pendapatan CAGR sebesar 24.9 persen selama periode perkiraan. Meningkatnya kejadian kanker di seluruh dunia serta meningkatnya angka kematian yang disebabkan oleh kanker diharapkan menjadi pendorong utama pertumbuhan pendapatan di pasar terapi sel CAR-T global selama periode perkiraan. Perluasan kegiatan uji klinis dengan kecepatan yang sangat tinggi, proliferasi merger dan akuisisi, dan daya pikat penawaran umum perdana adalah semua faktor yang berkontribusi terhadap pertumbuhan pendapatan di pasar terapi sel T CAR global.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Terapi Sel T CAR market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Terapi Sel T CAR market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Temuan signifikan tambahan dari laporan menunjukkan bahwa
Pada tahun 2021, segmen sel B besar menyebar limfoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with terapi sel T reseptor antigen chimeric, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell limfoma non-Hodgkin who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Perusahaan kunci yang saat ini beroperasi di pasar diselidiki lebih lanjut dalam laporan ini, seperti profil perusahaan, portofolio produk, strategi ekspansi, dan aliansi strategis mereka. Beberapa contoh dari jenis aliansi ini termasuk merger dan akuisisi, kolaborasi, dan usaha patungan. Selain itu, ini memberikan sorotan tentang pencapaian dan posisi keuangan perusahaan, serta wawasan tentang jangkauan pasar dan posisi global perusahaan.
Perusahaan yang diprofilkan di pasar Terapi Sel T CAR global:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd., dan Eli Lilly and Company .
Baca lebih lanjut tentang laporan pasar CAR T-Cell Therapy global di: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
